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Background
The use of inactivated autologous HIV-1 from infected
patients as an antigen formulation for a therapeutic vac-
cine involves the isolation and propagation of HIV in cell-
culture conditions fulfilling the clinical grade Good Man-
ufacturing Practice (GMP), and the development of anal-
ysis systems to detect adventitious agents. In this study we
present the development of heat inactivated autologous
HIV-1 produced Ex vivo to be used as immunogen in
human therapeutic vaccine (Clinical Trial DCV02).
Methods
Autologous HIV-1 was isolated from 14 infected subjects
(4.2 log HIV-1 cp RNA/mL plasma), by co-culture of the
CD4-enriched PBMCs from these infected patients with
CD4-enriched PBMCs pre-activated from healthy donors,
during 21 days in X-Vivo 20 media, 10% of AB human
serum and IL-2. Cell-culture supernatants were concen-
trated by ultrafiltration. Viral productions were analyzed
by ELISA p24Ag-HIV-1 and RNA cp/mL in the final prod-
uct. Adventitious agents were analyzed by cell culture in
PBMCs, MRC-5 and VERO cell lines, microbiology cul-
tures, gram and mycoplasma tests. The HIV-1 protease
(PR) sequence was also analyzed.
Results
To obtain de immunogen from 14 patients it was neces-
sary to perform 21 cell-cultures to produce the immuno-
gen in optimal cGMP conditions. From each patient, a
median of 80 mL of cell culture supernatant with a
median of 8,8 log HIV-1 cp RNA/mL were heat inactivated
and concentrated until a volume of 1 mL of final product
with 9.8 log HIV-1 cp RNA/mL. No differences were found
between HIV-1 PR sequences of cell culture and plasma.
Heat inactivation reached an infectivity reduction median
of 5.5 Log in 11 days PBMCs cell cultures.
Conclusion
Ex vivo isolation and production of autologous HIV-1 by
cell co-culture fulfilling clinical grade GMP for therapeutic
vaccine is feasible, but requires a concerted effort to guar-
antee the quality and safety of the final product.
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